On Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, reported that two abstracts on luspatercept have been accepted for presentation at the 14th International Symposium on Myelodysplastic Syndromes (MDS) in Valencia, Spain on May 3-6, 2017 (Press release, Acceleron Pharma, APR 6, 2017, View Source [SID1234518497]). Schedule your 30 min Free 1stOncology Demo! The oral presentation will include data from a Phase 2 study with luspatercept in lower-risk MDS populations, including first-line ring sideroblast-negative and -positive subpopulations. Luspatercept is being developed under a global partnership with Celgene.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentation
Title:
Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the PACE Study (Abstract #17-0245)
Session: Oral Session 3 (Valencia Conference Center, Auditorium 1)
Date: Saturday, May 6th
Time:
9:15 a.m. CEST
Poster presentation
Title:
Pharmacokinetics and Exposure-Response Relationship of Luspatercept in Patients with Anemia Due to Lower-Risk MDS: Preliminary Results from Phase 2 Studies (Abstract #17-0112)
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster I (Valencia Conference Center)
Date: Thursday, May 4th to Saturday, May 6th
The luspatercept clinical poster and slides from the oral presentation will be available immediately following the presentations at the conference in the "Science" section on Acceleron’s website, www.acceleronpharma.com.
About Luspatercept
Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Phase 3 clinical trials are underway to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the "MEDALIST" study) and in patients with beta-thalassemia (the "BELIEVE" study). For more information, please visit www.clinicaltrials.gov.